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Early in normal pregnancy (NP), maternal blood volume expands while systemic vascular resistance and systemic 
blood pressure both decline.1 These changes alter significantly 
in preeclampsia, a pregnancy-specific syndrome (affecting 5% 
to 10% of all pregnancies worldwide),2 which is defined by 
maternal new-onset hypertension and proteinuria or organ dys-
function, developing after 20 weeks of gestation.3 Preeclampsia 
is thought to originate as a result of poor placentation, caus-
ing endothelial dysfunction, disordered angiogenic balance and 
resultant hypertension, glomerular lesions, and hepatic failure.4,5
Nitric oxide (NO) is a potent vasodilator, considered to 
have major effects on gestational endothelial function.6 NO 
is synthesized by nitric oxide synthases (NOS), namely endo-
thelial NOS (eNOS), inducible NOS (iNOS), and neuronal 
NOS.7 Studies investigating circulating levels of NO in pre-
eclampsia have reported conflicting results.8 This is in contrast 
to studies that have shown that plasma from women with pre-
eclampsia elicits reduced endothelium-dependent vasodilata-
tion in isolated vessels. NO availability may be decreased9–11 
because of oxidative stress, vascular endothelial growth fac-
tor deficiency, or endogenous inhibitors, such as asymmetric 
dimethylarginine.12 It is assumed that most of the circulating 
NO derives from maternal endothelium. But the placenta may 
also contribute.
In the placenta, NOS is predominantly expressed in the 
syncytiotrophoblast, villous endothelium, and macrophages; 
the predominant isoform being eNOS.13–15 The multinucle-
ated syncytiotrophoblast layer lining the chorionic villi is the 
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interface between the maternal and fetal vascular systems16,17 
and could contribute to circulating NO. Here we investigate 
another possibility, namely, that syncytiotrophoblast-derived 
NOS could be exported to the mother in syncytiotrophoblast 
extracellular vesicles (STBEV) with the potential of systemi-
cally modulating maternal vascular response. STBEV are 
shed into the maternal circulation, detectable from week 10 
of gestation and in increasing amounts through pregnancy.18,19 
STBEV comprise 2 subgroups: microvesicles (STBMV, 100–
1000 nm), which are shed directly from the plasma mem-
brane in response to cell activation or death, and exosomes 
(STBEX, 20–200 nm), which are released by exocytosis from 
multivesicular bodies of the endosome.20 There is evidence 
that STBEV could allow communication between the mother 
and the fetus, in a manner dependent on the content of their 
cargo.21
Our hypothesis was whether STBEV might carry eNOS 
as part of their cargo. To investigate this, we examined 
whether eNOS was present on STBEV derived from NP 
and preeclampsia-perfused placental lobules, as well as cir-
culating STBMV from NP and preeclampsia peripheral vein 
blood (PB) and uterine vein blood (UV). We wanted to assess 
whether STBEV-bound eNOS (STBEV-eNOS) was functional 
and capable of producing NO, and whether its expression and 
activity was altered in preeclampsia.
Methods
Human Subjects
This project was approved by the Central Oxfordshire Research Ethics 
Committee C (REFS 07/H0607/74 & 07/H0606/148). All mothers 
undergoing elective caesarean section gave written informed consent 
for the use of their blood and placentas. Blood samples were collected 
in four 5-mL EDTA/citrate tubes using a 21-gauge needle. Samples 
were centrifuged at 1500g for 15 minutes at room temperature, and 
the supernatant was centrifuged again at 13 000g for 2 minutes to 
produce platelet-free plasma and stored in aliquots at −80°C. PB 
samples were from the left antecubital fossa, while UV samples were 
taken at caesarean section (after bladder reflection before the uterine 
incision was made). Placentae were collected within 10 minutes of 
delivery. Placentae from NP were from singleton pregnancies with no 
current or previous history of preeclampsia or hypertensive disorders. 
Preeclampsia patients were identified according to the criteria of the 
International Society for the Study of Hypertension in Pregnancy; 
hypertension was defined as new hypertension in the second half of 
pregnancy >140/90 mm Hg accompanied with new proteinuria >300 
mg per 24 hours. Clinical characteristics of preeclampsia patients and 
controls (NP) are described in Table. STBMV from plasma samples 
were matched for gestational age.
Cell Culture
Human umbilical vein endothelial cells were used as eNOS-positive 
control. Detailed Methods section is available in the online-only Data 
Supplement.
Immunohistochemistry
Immunohistochemical staining was performed using standard proto-
cols with NP placental tissue slide preparations. Detailed Methods 
section is available in the online-only Data Supplement.
Isolation and Characterization of STBEV
STBEV were prepared using a modified dual-lobe placental perfu-
sion system and differential centrifugation as previously described 
by us.22 Fresh STBMV were phenotyped by flow cytometry, using 
a BD LSRII flow cytometer (BD Biosciences), and STBEX were 
phenotyped by nanoparticle tracking analysis, using a NanoSight 
NS500 (Malvern, UK). The phenotype of STBEV was addition-
ally assessed by SDS-PAGE and Western blotting analysis for 
placental alkaline phosphatase (PlAP) positivity (PlAP is syn-
cytiotrophoblast specific) combined with the exosome markers 
ALIX, Syntenin, and CD9 to confirm exosomal phenotype because 
STBEX cannot be resolved by flow cytometry because of their size. 
STBMV and STBEX were assayed for protein using bicinchoninic 
acid assay before storage at −80°C.
Flow Cytometry Analysis
Perfusion-isolated STBMV from NP and preeclampsia placentae 
were interrogated by multicolor flow cytometry using the protocol 
and settings previously described22,23 and specifically interrogated for 
eNOS. Detailed Methods section is available in the online-only Data 
Supplement.
Circulating plasma STBMV from PB and UV were analyzed by 
flow cytometry using a previously described protocol,24 with addi-
tional modifications to exclude potential nonplacental extracellular 
vesicle (EV) contaminants. Detailed Methods section is available in 
the online-only Data Supplement.
Table. Clinical Data of Human Subjects
Patient Characteristics
Placental STBEV Plasma STBEV
P ValueNP (n=11) PE (n=8) NP (n=6) PE (n=6)
Age, y 35.5±1.5 32.4±1.6 31.8±2.4 30.7±2.4 NS, NS
Gestation age, wk 39+4±3 34+4±5.7 35+5±0.3 36+6±0.5 ****, NS
Mean no. of pregnancies 2.1±0.4 0.5±0.2 0.5±0.2 1.3±0.6 **, NS
Body mass index, kg/m2 32±2 32.1±3.5 21.8±0.8 28.2±2.3 NS
Max. proteinuria PCR, mg/mmol 5.5±0.2 204.1±77.4 0±0 360.2±162.8 ***, ††
Max. systolic pressure, mm Hg 127.3±4.3 168.8±8.3 116.7±2.6 161.2±7.7 ***, ††
Max. diastolic pressure, mm Hg 75.5±2.4  104.4±4 71±3.3 111.5±5.1 ****, ††
New-born weight, g 3999.2±152.5 1985±205.1 3641±198 2769±189 ****, †
Smoking history 3/11 3/8 0/6 0/6 …
Data presented as mean±SEM. NP indicates normal pregnancy; PCR, protein creatinine ratio; PE, preeclampsia; and STBEV, 
syncytiotrophoblast extracellular vesicles. Significant difference shown as P<0.05 (*, †), P<0.01 (**, ††), P<0.001 (***), 
P<0.0001 (****), or not significant (NS). Statistical comparison between NP and PE’s placental STBEV shown as * and plasma 
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Flow cytometry data were analyzed using FACSDiva software 8.0 
(BD Biosciences), and figures were generated using FlowJO version 
10 (Tree Star Inc, Ashland, OR). Given the issues described above 
about STBEX and flow cytometry, we investigated STBEV coexpres-
sion of eNOS and PlAP using paramagnetic immunobead depletion 
and Western blotting, described below.
Western Blotting
Western blots were performed using standard protocols with placen-
tal lysate, along with isolated STBMV and STBEX from NP and 
preeclampsia placentae. Detailed Methods section is available in the 
online-only Data Supplement.
Co-Immunoprecipitation Using Magnetic 
Dynabeads
3.25×107 Dynabeads (Life Technologies) were separately coated 
with 6 μg/mL of the following antibodies: (1) anti-eNOS (NOS3 
A9; Santa Cruz Biotech); (2) eNOS isotype control (IgG2a Clone 
DAK-GO5; Dako); (3) anti-PlAP antibody (NDOG2); and (4) PlAP 
isotype control (IgG1 Clone MOPC-21; BioLegend). STBMV or 
STBEX pooled from 4 NP (1 mg/mL) were incubated with anti-
human Fc receptor blocking reagent (10 μL; Miltenyi Biotec) for 10 
minutes at 4°C to block any nonspecific antigen binding (same pool 
was used at each experiment). Next, antibody-coated Dynabeads 
were incubated overnight at 4°C with 25 μg of protein from either 
STBMV (≈2.14×109 EV/mL) or STBEX (≈3.2×109 EV/mL) pools 
in 1 mL filtered PBS, as per manufacturer’s instructions. STBMV 
or STBEX bound to antibody-coated Dynabeads were separated 
and washed with PBS using a magnetic particle concentrator (Dynal 
MPC-S; ThermoFisher) and processed for Western blotting. See 
Methods section is available in the online-only Data Supplement for 
percentage calculations.
Dimerization Analysis
To investigate eNOS dimerization in STBMV and STBEX, low-
temperature SDS-PAGE was performed as previously described.25 
NP samples at 15 μg were loaded under nonreducing conditions 
onto a 4% to 12% SDS-PAGE gel and run at 5 mA overnight at 
4°C. Separated proteins were then transferred onto polyvinylidene 
difluoride membranes and blocked with 3% wt/vol BSA dissolved 
in Tris-buffered saline and Tween 20 for 1 hour prior to overnight 
incubation at 4°C with 0.6 μg/mL of anti-eNOS (NOS3-A; Santa 
Cruz) diluted in blocking buffer. Protein visualization was then 
performed on Western blot as described earlier.
NOS Activity Assay
NOS activity by STBMV and STBEX was determined using an 
ultrasensitive colorimetric NOS assay kit, which converts all NO 
metabolites to nitrite using nitrate reductase (NB78 and NB70; 
Oxford Biomedical Research). We followed the manufacturer’s 
protocol and depicted nitrite accumulation as NOS activity (ie, 
production of NO). STBMV and STBEX pools of 4 NP patients 
(different pools used at each experiment) were first incubated in dif-
ferent concentrations (0, 10, 25, 50, and 100 μg). NOS activity was 
also measured with or without specific eNOS inhibitor, NG-nitro-l-
arginine methyl ester (L-NAME; 1 mmol/L; Sigma-Aldrich), and 
the highly specific iNOS inhibitor, N-(3-(aminomethyl) bezyl) 
acetamidine) (2 μmol/L; Enzo Life Sciences).26 Inhibitors were 
incubated with STBMV and STBEX for 1 hour prior to analysis. 
Reactions were measured in triplicate, and absorbance was read 
at 540 nm.
Statistical Analysis
The data were analyzed using GraphPad 5 software. Normality test-
ing was performed using the Kolmogorov–Smirnov test and visual 
observation. The data were analyzed using paired or unpaired t test 
with Welch’s correction or 1-way analysis of variance, and data were 
presented as mean±SEM.
Results
Isolated STBEV Confirmed Microvesicular 
and Exosomal Phenotype
We first reconfirmed the expected microvesicular and exo-
somal phenotypes and sizes for STBEV (see Figure S1 in 
the online-only Data Supplement ). Immunoblots of STBEV 
showed an enrichment of the STBEV marker, PlAP, rela-
tive to placental lysates. This enrichment was seen in both 
STBMV and STBEX (Figure S1A). STBEX were enriched 
for the exosomal markers ALIX, Syntenin, and CD9 (Figure 
S1A). Freshly isolated STBEV were analyzed on nanopar-
ticle tracking analysis for size and particle number profiles. 
STBMV showed modal size of 323.2±7.1 nm with a broad 
size distribution, while STBEX were smaller (189.3±9.7 nm) 
with narrower size distribution (Figure S1B). Representative 
transmission electron micrographs confirmed the nanoparticle 
tracking analysis, and Western blot data showing STBMV was 
enriched for heterogeneous EV>200 nm, while STBEX con-
tained a more homogenous population with a range of 30 to 
200 nm EV (Figure S1C). These data confirmed that STBMV 
and STBEX had been successfully isolated.
Syncytiotrophoblast and STBEV Express eNOS but 
Not iNOS
Immunohistochemical analysis of placental tissue revealed 
eNOS expression primarily localized in the syncytiotropho-
blast cell layer of NP samples in comparison to negative 
staining of isotype control IgG2a (n=3; Figure 1A), confirm-
ing findings made previously by others.13–15 Similarly, eNOS 
expression was also shown in the placental lysates. We were 
also able to visualize eNOS expression in STBMV and STBEX 
isolated from NP (Figure 1B) and from preeclampsia (Figure 
1C) placentae. iNOS expression was not detectable in the 
syncytiotrophoblast cell layer (n=3; Figure 1D). Additionally, 
no expression of iNOS in either placental lysates, STBMV, 
or STBEX from NP (Figure 1E) or preeclampsia placentas 
(Figure 1F) was detected (n=3). Nevertheless, expression of 
iNOS was seen in positive control RAW 264.7 cells, reassur-
ing the antibody’s quality (Figure 1E and 1F). Positive PlAP 
expression indicated that the EV analyzed were derived from 
syncytiotrophoblast. The absence of iNOS prompted us to 
perform mass spectrometry.
Mass Spectrometry Data
We assessed a mass spectrometry analysis we have performed 
on placental lysate, STBMV and STBEX from NP (n=6) and 
preeclampsia (n=8) patients (Tannetta et Al, unpublished 
data), and specifically interrogated it for the presence of NOS 
isoforms (see Table S1). The mass spectrometry was clearly 
able to identify eNOS, but iNOS was not identified at the pro-
tein level. Given these confirmatory findings, we, therefore, 
focused on STBEV expressing eNOS.
Flow Cytometric Analysis of Ex Vivo and In Vivo–
Derived STBMV Reveal Coexpression of eNOS 
and PlAP
STBMV derived from NP and preeclampsia placental perfu-
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coexpression (n=6). Using the corresponding fluorescence 
minus one controls, our data revealed double eNOS and PlAP 
positivity of 30.3±8.5% in NP-derived STBMV and 6.3±3.3% 
in preeclampsia-derived STBMV (*P<0.05; Figure 2A).
Circulating STBMV were also analyzed by flow cytom-
etry in plasma prepared from paired PB and UV samples 
(n=8). PlAP and eNOS double-positive events per milliliter 
were significantly higher in UV (49 686±28 162) compared 
with PB (7723±2823) plasma samples, confirming STBMV-
bound eNOS consistent with their origin from the placenta 
(**P<0.01; Figure 2B).
Similarly, STBMV-bound eNOS was measured in ges-
tational age–matched plasma PB samples from NP and pre-
eclampsia patients (n=6). After exclusion of EV derived from 
other cells rather than the syncytiotrophoblast, the results 
showed a significant reduction in PlAP and eNOS double-
positive events per milliliter of plasma-derived STBMV 
from preeclampsia (12 798±7121) compared with NP 
(62 838±15 246; **P<0.01; Figure 2C). These data suggest 
that there is less plasma-derived STBMV-bound eNOS in pre-
eclampsia compared with NP.
eNOS and PlAP Are Expressed on the Same EV 
Population
Immunodepletion was used to further confirm STBMV and 
STBEX coexpression of eNOS and PlAP and exclude poten-
tial aggregation.
For Western blot analysis, we used anti-eNOS–coated 
beads to immunoprecipitate eNOS-positive STBEV, which 
were interrogated for the presence of PlAP. We also conversely 
Figure 1. Immunohistochemical staining 
of normal pregnancy (NP) placenta 
tissue and Western blot of NP and 
preeclampsia (PE)-derived placental 
lysate (PL), syncytiotrophoblast 
extracellular microvesicles (STBMV) 
and syncytiotrophoblast extracellular 
exosomes (STBEX; n=3). A, Placental 
tissue showing endothelial nitric oxide 
synthase (eNOS) staining (brown; left) 
on syncytiotrophoblast (STB) layer 
and IgG2a-negative staining (right). 
Immunoblot showing eNOS (140 kDa) 
and placental alkaline phosphatase 
(PlAP; 60 kDa) expression in PL, 
STBMV, and STBEX derived from NP 
(B) and PE (C) similar to expression of 
positive control, human umbilical vein 
endothelial cells (HUVEC). D, Placental 
tissue demonstrating lack of inducible 
nitric oxide synthases (iNOS) staining 
(left) and isotype control IgG1-negative 
staining (right). Immunoblot showing no 
expression for iNOS (131 kDa) though 
positive control, RAW, is expressed and 
PlAP (60 kDa) is also expressed in PL, 
STBMV, and STBEX derived from NP (E) 
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used anti-PlAP–coated beads to immunoprecipitate PlAP-
positive STBEV, which were then interrogated for eNOS. 
Figure 3A reveals that anti-eNOS–coated magnetic beads 
could pull out STBMV-bound eNOS, which were positive 
for PlAP. The converse experiment using anti-PlAP–coated 
beads revealed similar results, confirming that both species 
were bound on the same population of STBMV (Figure 3A). 
Interestingly, PlAP pull out yielded a greater signal for eNOS 
compared with the eNOS pull out, which may indicate that 
some eNOS is intravesicular. To assess the relative quanti-
ties of STBMV-bound eNOS or PlAP, we used nanopar-
ticle tracking analysis. The total concentration of STBMV 
was compared with the supernatant samples from the bead 
depletion experiments. This data showed that 35.5±4.2% 
of STBMV were eNOS positive and 64.3±0.4% were PlAP 
positive (n=3; Figure 3B), while IgG2a control was positive 
for 11.3±5.7%, and IgG1 control was positive for 11.4±3.4% 
(n=3; Figure 3C).
Analysis of the STBEX fraction (Figure 3D) revealed 
similar results. STBEX-bound eNOS comprised 36.7±6.6% 
while STBEX-bound PlAP was 39.2±5.8% of the initial prep-
aration (n=3; Figure 3E), while IgG2a control was positive 
for 10.8±4.5% and IgG1 control was positive for 15.1±5.8% 
(n=3; Figure 3F).
STBEV-eNOS Is Functional and Produce NO
eNOS dimer (260 kDa) and monomer (140 kDa) were sepa-
rated and visualized on Western Blot from ex vivo–derived 
STBMV and STBEX (n=3; Figure 4A), suggesting STBMV- 
and STBEX-bound eNOS are active. This was confirmed by 
demonstrating increasing dose-dependent NOS activity in 
terms of nitrite accumulation per hour (n=6 pooled STBEV; 
***P<0.001; Figure 4B) as the protein concentration of 
STBMV and STBEX was increased. Nitrite accumulation was 
reduced in STBMV and STBEX incubated with L-NAME (an 
eNOS inhibitor) compared with control (STBMV, *P<0.05; 
STBEX, *P<0.05, n=3; Figure 4C). STBMV and STBEX 
incubated with selective iNOS inhibitor N-(3-(aminomethyl) 
bezyl) acetamidine) (2 μM) showed no change compared with 
control (both ns, n=3; Figure 4D).
Ex Vivo STBEV-eNOS Reduced Activity in 
Preeclampsia
NOS activity was compared between STBEV from NP (n=11) 
and preeclampsia (n=8) samples. For STBMV, the overall data 
showed no statistical difference in NOS activity (Figure 5A). 
When we analyze the same data taking into account gesta-
tional age (Figure 5B), we are able to see that preeclampsia 
samples from patients with a gestational age most similar to 
the available controls show a reduction in NOS activity (>34 
weeks preeclampsia versus <40 weeks NP samples; *P<0.05). 
The earlier gestational ages are more difficult to interpret 
because of the lack of age-matched NP controls.
The STBEX showed an overall significant reduction in 
NOS activity (*P<0.05; Figure 5C), which persisted when we 
compared preeclampsia samples from patients with a gesta-
tional age most similar to controls (Figure 5D).
Taking STBMV and STBEX together, there is an over-
all reduction in NOS activity in preeclampsia compared with 
control.
Discussion
We have demonstrated for the first time that eNOS is coex-
pressed with PlAP, the syncytiotrophoblast marker, on both 
STBMV and STBEX isolated from ex vivo NP placentas by 
Western blot, flow cytometry, and paramagnetic immuno-
precipitation. Ex vivo–derived STBMV- and STBEX-bound 
eNOS exists as dimers, a feature required for NOS catalytic 
activity,27 and confirmed that these are capable of producing 
NO, which can be inhibited by L-NAME (an eNOS inhibitor). 
In addition, flow cytometry evaluation of in vivo–derived cir-
culating STBMV from matched PB and UV plasma revealed 
that STBMV-eNOS are released by syncytiotrophoblast and 
circulate in the maternal blood.
NO plays an important role in mediating NP vasodilation, 
while defective endothelial NO synthesis and bioavailability has 
Figure 2. Flow cytometry analysis of ex vivo syncytiotrophoblast extracellular microvesicles (STBMV) derived from normal pregnancy (NP) 
and preeclampsia (PE) placentae (n=6). A, STBMV-bound endothelial nitric oxide synthase (eNOS) expression were significantly lower in 
PE compared with NP (*P<0.05). Flow cytometry analysis of circulating in vivo STBMV derived from paired peripheral vein blood (PB) and 
uterine vein blood (UV) plasma (n=8). B, Double-positive eNOS and placental alkaline phosphatase (PlAP) events per milliliter were higher 
in UV compared with PB (**P<0.01). Flow cytometry analysis of circulating in vivo syncytiotrophoblast extracellular vesicles (STBEV) 
derived from matched PB plasma of NP and PE patients (n=6). C, PlAP and eNOS double-positive STBMV events per milliliter were 




 http://ahajournals.org by on O
ctober 15, 2018
Motta-Mejia et al  Reduced eNOS Activity in STBEV From PE Patients  377
been associated with preeclampsia.28,29 This is the first study to 
reveal ex vivo–derived STBMV and STBEX isolated from pla-
cental perfused lobes to have less eNOS activity in preeclamp-
sia in comparison to controls. Similarly, in vivo–derived plasma 
STBMV analyzed by flow cytometry showed less STBMV-
bound eNOS expression in preeclampsia compared with NP.
We were unable to observe iNOS expression in NP syn-
cytiotrophoblast and its derived STBEV either by Western 
blotting or mass spectrometry. iNOS expression and activity 
has been described by some in syncytiotrophoblast and pla-
centa lysate.14,30,31 iNOS differences between normal and 
hypertensive pregnancies have been reported,32,33 while other 
studies have reported the absence of iNOS in the syncytiotro-
phoblast34,35 and a debateable relationship between iNOS and 
preeclampsia.36 Nevertheless, we think eNOS is the principal 
isoform bound to STBMV and STBEX.
Several studies corroborate our findings. It has been 
reported that isolated EV from plasma exert various effects 
Figure 3. Immunobead depletion and nanoparticle tracking analysis (NTA) profiles of syncytiotrophoblast extracellular microvesicles 
(STBMV) and syncytiotrophoblast extracellular exosomes (STBEX) pools from normal pregnancy (NP; n=3). A, Representative immunoblot 
showing endothelial nitric oxide synthase (eNOS) and placental alkaline phosphatase (PlAP) coexpression on STBMV pool (Total) and 
STBMV pulled out (PO) with anti-eNOS Dynabeads, anti-PlAP Dynabeads, anti-IgG2a Dynabeads (isotype control for eNOS), and anti-
IgG1 Dynabeads (isotype control for PlAP). B, Representative NTA size vs number profiles of STBMV pool (solid line), supernatant from 
post-incubation with anti-eNOS Dynabeads (dashed line) and anti-PlAP Dynabeads (dotted line). C, STBMV pool (solid line), supernatant 
of post incubation with anti-IgG2a Dynabeads (dashed line) and anti-IgG1 Dynabeads (dotted line). D, Representative immunoblot 
showing eNOS and PlAP coexpression on STBEX pool (Total) and STBEX PO with anti-eNOS, anti-PlAP, anti-IgG2a, and anti-IgG1 
Dynabeads. E, Representative NTA size vs number profiles of STBEX pool alone (solid line), supernatant from post-incubation with anti-
eNOS (dashed line) and anti-PlAP (dotted line) Dynabeads. F, STBEX pool (solid line), supernatant of post incubation with anti-IgG2a 
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Figure 4. Syncytiotrophoblast 
extracellular microvesicles (STBMV) 
and syncytiotrophoblast extracellular 
exosomes (STBEX) express functional 
endothelial nitric oxide synthase 
(eNOS) and produce nitric oxide (NO). 
A, Dimerization of syncytiotrophoblast 
extracellular vesicles (STBEV) 
immunoblot image showing eNOS dimer 
(260 kDa) and eNOS monomer (140 
kDa) expressed in human umbilical vein 
endothelial cells (HUVEC), STBMV, and 
STBEX (n=3). B, STBMV (***P<0.001) 
and STBEX (***P<0.001) pools showed 
NO production in a dose-dependent 
manner (n=6). C, 25 μg pool of STBMV 
and STBEX preincubated for 1 hour with 
1 mmol/L of NG-nitro-l-arginine methyl 
ester (L-NAME), NOS inhibitor, showed 
significant reductions in NO production 
compared with controls (both *P<0.05; 
n=3). D, 25 μg pool of STBMV and 
STBEX preincubated for 1 hour with 
2 μmol/L N-(3-(aminomethyl) bezyl) 
acetamidine) (1400W), inducible nitric 
oxide synthases (iNOS)–specific inhibitor, 
showed no changes in NO production 
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on endothelial and trophoblast cells according to the physi-
ological/pathological state of the pregnant woman.37,38 A 
decrease in expression and activity of eNOS bound to circu-
lating nonpregnant EV has also been associated with cardio-
vascular diseases.39 Kao et al40 showed a significant increase 
in superoxide levels and impaired endothelial dysfunction 
in rat uterine arteries incubated with human preeclampsia 
plasma. Interestingly, L-NAME abolished this uterine artery 
vasodilation in both NP- and preeclampsia-derived plasma-
treated vessels, suggesting that this effect was because of 
eNOS. Their findings support ours, although circulating fac-
tors rather than STBEV were described.
We hypothesize that decreased systemic eNOS in the form 
of circulating STBEV-eNOS may contribute to the reduced 
bioavailability of NO seen in preeclampsia, possibly affecting 
vascular functions. We are uncertain as to whether eNOS is 
donated to endothelial cells or whether NO is produced close 
to the endothelial cell and work to elucidate this is ongoing. 
We therefore interpret our data with some caveats. Although 
we show decreased NO production by STBEV-eNOS, there 
may also be a few other factors that contribute to the reduction 
of NO bioavailability. There may be (1) variation in NOS gene 
expression and activity; (2) lower substrate levels for NOS; 
(3) elevated inhibitors of NOS; or (4) increased breakdown 
of NO per se.41 Decreased NO release would not necessarily 
be limited by the shedding of less STBEV-eNOS from pla-
centa. Other cell types expressing eNOS, such as platelets,42 
endothelial progenitor cells,43 or circulating EV derived from 
endothelial cell and red blood cell,39 may contribute to overall 
NO bioavailability.
Our study has some limitations. Exosomes cannot be 
readily examined by routine flow cytometry because their 
size is below the limit of resolution. Thus, we were unable 
to measure STBEX-bound eNOS expression as we did with 
STBMV. Notwithstanding, we did see decreased levels of NO 
production in preeclampsia-derived STBEX. It is difficult to 
age match placental tissue in a disease which typically occurs 
earlier in pregnancy. We have attempted to mitigate this by 
using placentae from patients who developed preeclampsia 
later in pregnancy, but this limitation is common to all pre-
eclampsia studies. Also, despite measuring STBMV-bound 
eNOS expression in plasma, attempts to measure NO pro-
duction from plasma-derived STBMV and STBEX were 
unsuccessful because we were below the NOS assay limits 
of detection.
In conclusion, our data show that both STBMV and 
STBEX carry functionally active eNOS. Also, iNOS is not 
expressed in either STBMV or STBEX, thus, making STBEV-
eNOS the principal moiety. Furthermore, STBEV-eNOS 
activity is reduced in preeclampsia, significantly in STBEX-
bound eNOS. These findings suggest that STBEV-eNOS 
might contribute to the overall decreased NO bioavailability 
seen in preeclampsia.
Figure 5. Nitric oxide synthase (NOS) activity of syncytiotrophoblast extracellular microvesicles (STBMV) and syncytiotrophoblast 
extracellular exosomes (STBEX) isolated from perfused normal pregnancy (NP) and preeclampsia (PE) placentae (n=11 and n=8, 
respectively). STBMV (A) from PE placentae showed a no overall reduction in NO production compared with NP (ns; P=0.2416). Analysis 
of the same data as a function of the gestational age of the samples (B) shows a decrease in NO production in samples closest in 
gestational age to controls (PE>34 weeks vs NP<40 weeks; *P<0.05). While STBEX (C) from PE showed a significant reduction in NO 
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Perspectives
This study demonstrates that STBEV carry active eNOS into 
the maternal circulation. Importantly, the lower circulating 
STBEV-eNOS seen in preeclampsia might contribute to the 
diminished NO reported in this disease.
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What Is New?
•	Ex vivo and in vivo circulating–derived placental extracellular vesicles 
express functional endothelial nitric oxide synthase (eNOS), not inducible 
nitric oxide synthase.
•	The plasma circulating levels of syncytiotrophoblast extracellular mi-
crovesicles–bound eNOS is significantly reduced in patients with pre-
eclampsia compared with gestational age–matched controls.
•	The circulating syncytiotrophoblast extracellular microvesicles–bound 
eNOS is produced by the placenta and elevated in uterine vein blood 
compared with peripheral blood.
•	Ex vivo syncytiotrophoblast extracellular microvesicles and syncytiotro-
phoblast extracellular exosomes–bound eNOS activity is significantly 
decreased overall in preeclampsia compared with controls.
What Is Relevant?
•	Preeclampsia is a major cause of maternal morbidity and fetus mortality.
•	Decreased circulating syncytiotrophoblast extracellular vesicles–bound 
eNOS might contribute to the overall decreased nitric oxide bioavailability 
seen in preeclampsia.
•	Placental syncytiotrophoblast extracellular vesicles may play a role in 
signaling from the placenta to the maternal vascular system.
Summary
The presence of trophoblast-derived circulating eNOS potentially 
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